Ayana is a pharmaceutical company focused on development of Liposomal Therapeutics for the treatment of cancer

Founded in 2012 by Prof. Chezy Barenholz (co-inventor of Doxil® - Doxorubicin-HCl Liposomal Injection)

Lead product LC101 (Doxorubicin-HCl Liposomal Injection) ANDA submitted to FDA for obtainment of U.S. marketing authorization for Ovarian Cancer, Multiple Myeloma and AIDS-related Kaposi’s Sarcoma

Secured FDA accredited, cGMP manufacturing facility to support commercial launch

Strategic agreement with tier 1 pharma company for commercialization of LC101 in the U.S. market

Overall $500m WW market opportunity with very few competitors due to high entry barriers (i.e. complex nonotechnology drug)

Acomplished company leadership